Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

October 4, 2019 admin Healthcare, Investor Presentations Comments Off on Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

Hoth Therapeutics, Inc. (NASDAQ: HOTH)

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Next Super Stock investor conference presentation 9/26/2019

Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, and acne.

Dermatology is a hot sector, and Pfizer (NYSE: PFE) recently paid $4.9 billion for HOTH peer company, Anacor whose lead product, Eucrisa, is a topical treatment for mild to moderate eczema.

With a shortened path towards regulatory approval, unique technology, and multiple near-term catalysts for value creation, HOTH represents a compelling opportunity. 

Watch this presentation as CEO Robb Knie explain’s HOTH’s unique value proposition for investors.




Related Articles

Healthcare

CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]

Healthcare

CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

January 13, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

VANCOUVER, Washington, Jan. 13, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]